The Swedish BioFINDER Study

The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.

BioFINDER
One

The first BioFINDER study, launched in 2008, focusing on the early stages of Alzheimer’s and Parkinson’s diseases and related disorders. It includes longitudinal assessments over a period of 6-10 years.

BioFINDER
Two

The second BioFINDER study, launched in 2017, is more comprehensive than BioFINDER One. It includes a larger number of study participants and cutting-edge brain imaging such as tau-PET in all study partcipants.

BioFINDER
Sleep

The BioFINDER Sleep study targeting prodromal Parkinson’s disease was initiated in 2021. It encompasses individuals with REM-sleep behavior disorder and those in the early stages of Parkinson’s disease.

BioFINDER
Preclinical AD

The study, launched in 2022, screens a general population with a blood test to detect preclinical (pre-symptomatic) Alzheimer’s disease. Its goals are to deepen our understanding of the initial stages of the disease and to optimize future primary and secondary prevention trials.

BioFINDER
Primary Care

This BioFINDER study was launched in 2020. It includes diverse patient populations with cognitive symptoms at different primary care centers. The main aim is to improve the diagnostic and prognostic work-up in primary care of neurocognitive disorders using blood biomarkers and brief cognitive tests.

BioFINDER
Memory Clinic

This BioFINDER study, launched in 2023, is complementary to the BioFINDER Primary Care study, but targets a Memory clinic population in a secondary care setting.

News articles

  • Blood Tests: Not Just for the Impaired?

    In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease...

    Read more...

  • Looking Good: Immunoassays for Blood Markers

    For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical...

    Read more...
More news...

X posts

BioFINDER Follow 711 1,501

biofinder_study
biofinder_study avatar BioFINDER @biofinder_study ·
16 Sep 1967846363993186667

🚨Paper alert🚨
New publication in @JAMANeuro led by @gesalbla. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer's disease in cognitively unimpaired individuals.

A 🧵...

Image for twitter card

Plasma P-Tau217 to Identify Preclinical AD

This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in ...

jamanetwork.com
biofinder_study avatar BioFINDER @biofinder_study ·
16 Sep 1967846381734989902

🙏Many thanks to all collaborators in this large study including 12 international cohorts: @DivyaBali06 @A_OrdunaDolado @JosephTherr @EStomrud @NiklasMattsson4 @EmmaCoomans @CharlotteTeuni1 @NesrineR95 @JuandoGispert @vincentDore2 @AzadehFeizpour

biofinder_study avatar BioFINDER @biofinder_study ·
16 Sep 1967846383609958755

@DAlcoleaR @sylv_villeneuve @pedrorosaneto @SuzanneESchind1 @RikOssenkoppele @OskarHansson9 with data from @amsterdamumc @BarcelonaBeta @MayoClinicNeuro @mcgillu @prevent_ad @WashUMedADRC @WisconsinADRC… and those not in X.

biofinder_study avatar BioFINDER @biofinder_study ·
15 Sep 1967579467569832026

🚨New publication in Nature Medicine!
In this study, we demonstrate that a brief, self-administered cognitive test battery can reliably identify individuals with cognitive impairment in a primary care setting.
Details:
Full paper: https://www.nature.com/articles/s41591-025-03965-4

Image for twitter card

Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and...

Nature Medicine - A brief, self-administered digital cognitive test, in combination with a blood test, accurately dete...

www.linkedin.com
biofinder_study avatar BioFINDER @biofinder_study ·
15 Sep 1967579469641900180

The study was led by PhD students Pontus Tideman and @karlssonlinda1. Thank you also to all co-authors: @ErikRubenSmith @NiklasMattsson4 @EStomrud @SebastianPalmqv @OskarHansson9 and those not on X.

biofinder_study avatar BioFINDER @biofinder_study ·
5 Sep 1963972250899460187

🚨New paper alert! Our study led by @teanijarv investigated why some individuals with Alzheimer’s disease (AD) develop hemispheric asymmetry in tau pathology and what drives this phenomenon.
Out now in Nature Communications! 🔗Full article:
A thread🧵👇

Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s...

Nature Communications - Asymmetrical distribution of tau pathology in Alzheimer’s disease is linked to asymmetrical am...

doi.org
biofinder_study avatar BioFINDER @biofinder_study ·
5 Sep 1963972271380582538

7/🧵 These results suggest that hemispheric difference in Aβ deposition, rather than reduction in connectivity, is associated with asymmetric tau accumulation, highlighting regional vulnerability as a crucial factor in determining the distribution of AD pathology.

biofinder_study avatar BioFINDER @biofinder_study ·
5 Sep 1963972274463424950

Big thanks to all co-authors and collaborators: @RikOssenkoppele @ErikRubenSmith @LECollij @aitchbi @jorittmo @karlssonlinda1 @DaniellevWe @JakeVogel @EStomrud @SebastianPalmqv @NiklasMattsson4 @NicolaSpotorno @OskarHansson9 + those not on X

More posts...